Introducing ENTYCE®

(Capormorelin oral solution)

Now your veterinarian can help stimulate appetite in your dog.

Now there is a therapeutic that is FDA-approved specifically for appetite stimulation in dogs. ENTYCE mimics ghrelin (the “hunger hormone”) to trigger the feeling of hunger and is proven to effectively and safely stimulate appetite in dogs.

When a dog stops eating, it can be the first sign to indicate he or she is sick (and may be the only sign). Decreased appetite can lead to serious nutritional deficiencies and decreased quality of life.

ENTYCE assists in filling a serious unmet need to safely and effectively stimulate appetite while your veterinarian is diagnosing or treating your dog’s underlying health conditions. ENTYCE can help raise the standard of care for dogs that are inappetent.


ENTYCE is a flavored oral solution that is convenient to administer once daily. To administer ENTYCE, the bottle should be shaken gently and then the appropriate amount of solution withdrawn using the provided syringe. The syringe should be rinsed between treatment doses.


Inappetence is defined as a reduction in or lack of appetite. It may be associated with a variety of conditions or diseases, and can be challenging to treat. Early clinical intervention is important to prevent subsequent loss of body weight and complications.

There are varying levels of inappetence, including decreased appetite, changes in appetite and refusal to eat any food, which all can lead to drastic weight loss.

Inappetence or reduced appetite is extremely important to address as there can be many complications of long-term inadequate nutritional intake, including impaired quality of life.

Signs of inappetence may include:

  • Decreased interest in or enthusiasm for food
  • Weight loss
  • Muscle wasting
  • Lip smacking
  • Poor hair coat

There are many potential causes of inappetence in dogs, including both acute and chronic diseases, medications and psychological problems (e.g., stress or changes in routine, environment or diet).1

Treatment Options

The primary goals in managing inappetence are to diagnose and treat the underlying disease and reinstate adequate nutrition by stimulating appetite.1

The therapeutic approach to inappetence includes:

  • Removing or modifying any medications that may be causing inappetence
  • Removing or modifying any environmental stressors
  • Administering appetite-stimulating therapy

The use of an appetite stimulant may be recommended by a veterinarian during the initial diagnostic work-up while the cause of inappetence is being investigated.2

Until the approval of ENTYCE, there was no FDA-approved therapeutic for appetite stimulation in dogs.

1Ettinger SJ, Feldman EC. Textbook of Veterinary Internal Medicine. Vol 1. 7th ed. St. Louis, MO: Saunders Elsevier; 2010.
2 Baldwin K, et al. AAHA nutritional assessment guidelines for dogs and cats. J Am Anim Hosp Assoc. 2010; 46:285–96.

Ask Your Veterinarian

ENTYCE has been thoroughly tested in several research studies. Ask your veterinarian for more details on how it could help stimulate the appetite of your dog.

IMPORTANT SAFETY INFORMATION: ENTYCE® (capromorelin oral solution) is for use in dogs only. Do not use in breeding, pregnant or lactating dogs. Use with caution in dogs with hepatic dysfunction or renal insufficiency. Adverse reactions in dogs may include diarrhea, vomiting, polydipsia, and hypersalivation. Should not be used in dogs that have a hypersensitivity to capromorelin. Please see the full Prescribing Information for more detail.

Are You a Veterinary Professional?

Learn more about how ENTYCE could provide appetite stimulation for your canine patients.

Other therapeutics from Aratana

Nocita Logo

NOCITA® (bupivacaine liposome injectable suspension)

provides post-operative pain relief for cranial cruciate ligament surgery for up to 72 hours.

Now you can be sure dogs are getting the post-surgical pain relief they need even after they leave your clinic.

IMPORTANT SAFETY INFORMATION: NOCITA® (bupivacaine liposome injectable suspension) is for use in dogs only. Do not use in dogs younger than 5 months of age, dogs used for breeding, or in pregnant or lactating dogs. Do not administer by intravenous or intra-arterial injection. Adverse reactions in dogs may include discharge from incision, incisional inflammation and vomiting. Avoid concurrent use with bupivacaine HCl, lidocaine or other amide local anesthetics. Please see the full Prescribing Information for more detail.